MedTrace Logo

UPBEAT: Using Polygenic Scores to Guide BB Therapy in HF With Mildly Reduced EF

NCT07054489 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-05-07

No results posted yet for this study

Summary

This study will use polygenic scores, a tool which describes differences in genetics, to examine effectiveness of beta blocker medication in heart failure patients with ejection fraction of 41-50 percent. The study will also assess beta blockers' effect on the changes in left ventricular end-systolic volume index by MRI.

Conditions

Interventions

OTHER

Beta blocker

Participants randomized to intervention will be dosed and titrated on beta blocker according to study protocol.

Sponsors & Collaborators

  • David Lanfear

    lead OTHER

Principal Investigators

  • David Lanfear, MD · Henry Ford Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-30
Primary Completion
2027-06-30
Completion
2027-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07054489 on ClinicalTrials.gov